Abstract:BACKGROUND:The National Comprehensive Cancer Network's Rectal Cancer Guideline Panel recommends American Joint Committee of Cancer and College of American Pathologists (AJCC/CAP) tumor regression grading (TRG) system to evaluate pathologic response to neoadjuvant chemoradiotherapy for locally advanced rectal cancer (LARC). Yet, the clinical significance of the AJCC/CAP TRG system has not been fully defined. MATERIALS AND METHODS:This was a multicenter, retrospectively recruited, and prospectively maintained cohort study. Patients with LARC from one institution formed the discovery set, and cases from external independent institutions formed a validation set to verify the findings from discovery set. Overall survival (OS), disease-free survival (DFS), local recurrence-free survival (LRFS), and distant metastasis-free survival (DMFS) were assessed by Kaplan-Meier analysis, log-rank test, and Cox regression model. RESULTS:The discovery set (940 cases) found, and the validation set (2,156 cases) further confirmed, that inferior AJCC/CAP TRG categories were closely /ccorrelated with unfavorable survival (OS, DFS, LRFS, and DMFS) and higher risk of disease progression (death, accumulative relapse, local recurrence, and distant metastasis) (all p < .05). Significantly, pairwise comparison revealed that any two of four TRG categories had the distinguished survival and risk of disease progression. After propensity score matching, AJCC/CAP TRG0 category (pathological complete response) patients treated with or without adjuvant chemotherapy displayed similar survival of OS, DFS, LRFS, and DMFS (all p > .05). For AJCC/CAP TRG1-3 cases, adjuvant chemotherapy treatment significantly improved 3-year OS (90.2% vs. 84.6%, p < .001). Multivariate analysis demonstrated the AJCC/CAP TRG system was an independent prognostic surrogate. CONCLUSION:AJCC/CAP TRG system, an accurate prognostic surrogate, appears ideal for further strategizing adjuvant chemotherapy for LARC. IMPLICATIONS FOR PRACTICE:The National Comprehensive Cancer Network recommends the American Joint Committee of Cancer and College of American Pathologists (AJCC/CAP) tumor regression grading (TRG) four-category system to evaluate the pathologic response to neoadjuvant treatment for patients with locally advanced rectal cancer; however, the clinical significance of the AJCC/CAP TRG system has not yet been clearly addressed. This study found, for the first time, that any two of four AJCC/CAP TRG categories had the distinguished long-term survival outcome. Importantly, adjuvant chemotherapy may improve the 3-year overall survival for AJCC/CAP TRG1-3 category patients but not for AJCC/CAP TRG0 category patients. Thus, AJCC/CAP TRG system, an accurate surrogate of long-term survival outcome, is useful in guiding adjuvant chemotherapy management for rectal cancer.

Can Tumor Regression Grade Influence Survival Outcome in Ypt3 Rectal Cancer?

Feasibility Of Relatively Low Neoadjuvantradiation Doses For Locally Advanced Rectal Cancer: A Propensity Score-Matched Analysis

College of American Pathologists Tumor Regression Grading System for Long-Term Outcome in Patients with Locally Advanced Rectal Cancer.

The Ypt May Better Predict the Efficacy of Neoadjuvant Chemoradiotherapy Than Tumor Regression Grade in Locally Advanced Rectal Cancer Patients Diagnosed Ypt1-4N0.

Neoadjuvant Radiotherapy Improves Overall Survival for T3/4N+M0 Rectal Cancer Patients: a Population-Based Study of 20300 Patients

Tumor Regression Grades: Potential Outcome Predictor of Locally Advanced Rectal Adenocarcinoma after Preoperative Radiotherapy.

Tumor Regression Grade As a Prognostic Factor in Metastatic Colon Cancer Following Preoperative Chemotherapy

Tumor pathological response and downstaging of locally advanced rectal cancer after neoadjuvant chemoradiotherapy: comparison of two radiation dose schedules

Criteria of tumor regression grade and its application in diagnosis and treatment of rectal cancer

New Tumour Regression Grade for Rectal Cancer after Neoadjuvant Therapy and Radical Surgery

Associations of tumor regression grade with outcomes in patients with locally advanced rectal cancer treated with preoperative two-week course of radiotherapy

The Correlation Between Tumor Regression Grade and Retrieved Lymph Nodes Status in Locally Advanced Rectal Cancer after Neoadjuvant Treatment: Results from a Prospective Study

Survival landscape of different tumor regression grades and pathologic complete response in rectal cancer after neoadjuvant therapy based on reconstructed individual patient data

Stratified Prognostic Value of Pathological Response to Preoperative Treatment in yp II/III Rectal Cancer

Predictors and Risk Factors of Pathologic Complete Response Following Neoadjuvant Chemoradiotherapy for Rectal Cancer: A Population-Based Analysis

Lymph Nodes Regression Grade is a Predictive Marker for Rectal Cancer after Neoadjuvant Therapy and Radical Surgery

College of American Pathologists Tumor Regression Grading System for Long-Term Outcome and Adjuvant Chemotherapy in Patients with Locally Advanced Rectal Cancer: Result from a Multicentre, Observational, Cohort Study

Prognostic analysis of rectal cancer patients after neoadjuvant chemoradiotherapy: different prognostic factors in patients with different TRGs

Tumor regression grade combined with post‐therapy lymph node status: A novel independent prognostic factor for patients treated with neoadjuvant therapy followed by surgery in locally advanced gastroesophageal junction and gastric carcinoma

Correlation Between Tumor Regression Grade and Clinicopathological Parameters in Patients With Squamous Cell Carcinoma of the Esophagus Who Received Neoadjuvant Chemoradiotherapy

The prognostic significance of the treatment response of regional lymph nodes and the refinement of the current TNM staging system in locally advanced rectal cancer after neoadjuvant chemoradiotherapy